Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration

European Journal of Clinical Pharmacology

Volumn 66, Issue 12, 2010, Pages 1235-1245

  Ahn, Byung Jin ^a   Choi, Moon Ki ^b   Park, Young Suk ^b   Lee, Jeeyun ^b   Park, Se Hoon ^b   Park, Joon Oh ^b   Lim, Ho Yeong ^b   Kang, Won Ki ^b   Ko, Jae Wook ^c   Yim, Dong Seok ^d  

^a Dongguk University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Samsung Medical Center   (South Korea)

^d NONE

Author keywords

CPT 11; Gastric cancer; Intraperitoneal administration; NONMEM; Pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PERITONEAL FLUID LEVEL; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; PERITONEUM METASTASIS; PRIORITY JOURNAL; STEADY STATE; STOMACH ADENOCARCINOMA; TIME; TOTAL STOMACH RESECTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COHORT STUDIES; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MODELS, THEORETICAL; NEOPLASM SEEDING; STOMACH NEOPLASMS;

EID: 78649282266     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0885-3     Document Type: Article

References (22)

1. GG Chabot 1997 Clinical pharmacokinetics of irinotecan Clin Pharmacokinet 33 4 245 259 1:CAS:528:DyaK2sXntVGgtrg%3D 10.2165/00003088-199733040-00001 9342501
2. RH Mathijssen RJ van Alphen J Verweij WJ Loos K Nooter G Stoter A Sparreboom 2001 Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 7 8 2182 2194 1:CAS:528:DC%2BD3MXmsVOmsbg%3D 11489791
3. Stella VH, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley J (eds) (2007) Prodrugs challenges and rewards. Springer/AAPS Press, New York
4. K Sano M Yoshikawa S Hayasaka K Satake Y Ikegami H Yoshida T Ishikawa S Sawada S Tanabe 2003 Simple non-ion-paired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives J Chromatogr B Analyt Technol Biomed Life Sci 795 1 25 34 1:CAS:528:DC%2BD3sXmvVKnsro%3D 10.1016/S1570-0232(03)00485- 9 12957166 (Pubitemid 37289422)
5. TG Burke Z Mi 1994 The structural basis of camptothecin interactions with human serum albumin: impact on drug stability J Med Chem 37 1 40 46 1:CAS:528:DyaK2cXksFWqtA%3D%3D 10.1021/jm00027a005 8289200
6. Choi MK, Ahn BJ, Yim DS, Park YS, Kim S, Sohn TS, Noh JH, Heo JS, Lee J, Park SH, Park JO, Lim HY, Kang WK (2010) Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. Cancer Chemother Pharmacol. doi: 10.1007/s00280-010-1272-6
7. A Sparreboom MJ de Jonge P de Bruijn E Brouwer K Nooter WJ Loos RJ van Alphen RH Mathijssen G Stoter J Verweij 1998 Irinotecan (CPT-11) metabolism and disposition in cancer patients Clin Cancer Res 4 11 2747 2754 1:CAS:528:DyaK1cXns1Ogur0%3D 9829738
8. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2009) Prediction corrected visual predictive checks. Available at: http://www.go-acop.org/ acop2009/posters
9. R Xie RH Mathijssen A Sparreboom J Verweij MO Karlsson 2002 Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis J Clin Oncol 20 15 3293 3301 1:CAS:528:DC%2BD38XmsF2rs7w%3D 10.1200/JCO.2002.11.073 12149304 (Pubitemid 34835675)
10. GG Chabot D Abigerges G Catimel S Culine M de Forni JM Extra M Mahjoubi P Herait JP Armand R Bugat, et al. 1995 Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials Ann Oncol 6 2 141 151 1:STN:280:DyaK2Mzgs1Cjuw%3D%3D 7786822
11. G Catimel GG Chabot JP Guastalla A Dumortier C Cote C Engel A Gouyette A Mathieu-Boue M Mahjoubi M Clavel 1995 Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors Ann Oncol 6 2 133 140 1:STN:280:DyaK2Mzgs1Cjug%3D%3D 7786821
12. CE Klein E Gupta JM Reid PJ Atherton JA Sloan HC Pitot MJ Ratain H Kastrissios 2002 Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide Clin Pharmacol Ther 72 6 638 647 1:CAS:528:DC%2BD3sXltF2qtw%3D%3D 10.1067/mcp.2002.129502 12496745 (Pubitemid 36021003)
13. M Maruyama Y Toukairin H Baba N Kure T Nagahama M Ebuchi 2001 Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers Gan To Kagaku Ryoho 28 11 1505 1507 1:STN:280:DC%2BD3Mnmt1Kkuw%3D%3D 11707965
14. S Natsui M Maruyama T Ochiai K Hasegawa I Takashima T Nagahama M Ebuchi 2002 Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11 Gan To Kagaku Ryoho 29 12 2188 2190 12484033
15. S Guichard E Chatelut I Lochon R Bugat M Mahjoubi P Canal 1998 Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice Cancer Chemother Pharmacol 42 2 165 170 1:CAS:528:DyaK1cXjslWmu74%3D 10.1007/s002800050801 9654118 (Pubitemid 28267299)
16. M Maruyama T Nagahama Y Yuasa 1999 Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis Anticancer Res 19 5B 4187 4191 1:CAS:528:DC%2BD3cXktlSr 10628373
17. S Ragot P Marquet F Lachatre A Rousseau E Lacassie JM Gaulier JL Dupuy G Lachatre 1999 Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry J Chromatogr B Biomed Sci Appl 736 1-2 175 184 1:CAS:528: DyaK1MXnsl2lsb4%3D 10.1016/S0378-4347(99)00452-1 10676997
18. S Khan A Ahmad I Ahmad 2003 A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38) Biomed Chromatogr 17 8 493 499 1:CAS:528:DC%2BD3sXhtVWgsbnE 10.1002/bmc.257 14648604 (Pubitemid 38008951)
19. S Poujol F Pinguet F Malosse C Astre M Ychou S Culine F Bressolle 2003 Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies Clin Chem 49 11 1900 1908 1:CAS:528:DC%2BD3sXosleqsL0%3D 10.1373/clinchem.2003.023481 14578322 (Pubitemid 37340325)
20. JG Slatter LJ Schaaf JP Sams KL Feenstra MG Johnson PA Bombardt KS Cathcart MT Verburg LK Pearson LD Compton LL Miller DS Baker CV Pesheck RS Lord 3rd 2000 Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients Drug Metab Dispos 28 4 423 433 1:CAS:528:DC%2BD3cXitFeqsbk%3D 10725311
21. Y Sasaki Y Yoshida K Sudoh H Hakusui H Fujii T Ohtsu H Wakita T Igarashi K Itoh 1995 Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11 Jpn J Cancer Res 86 1 111 116 1:CAS:528:DyaK2MXjvV2ht7w%3D 7737902
22. A Hamada A Aoki H Terazaki K Ito K Yokoo Y Sasaki H Saito 2005 Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient Ther Drug Monit 27 4 536 538 1:CAS:528:DC%2BD2MXmsV2is78%3D 10.1097/01.ftd.0000165505.01298.00 16044114 (Pubitemid 41098832)